Business Wire

Nikon’s First European Nikon BioImaging Lab Now Open in Leiden

5.10.2021 07:00:00 EEST | Business Wire | Press release

Share

Nikon Europe B.V. has announced that its first European Nikon BioImaging Lab (NBIL) based in the prestigious Leiden Bio Science Park (LBSP) is now officially open.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005909/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Speakers at Nikon BioImaging Lab Inauguration ceremony (Photo: Business Wire)

The official opening took place on September 22nd with a welcome by Ziryan Othman, Team Leader Biotechnology Solutions, Nikon Europe Healthcare Division, followed by addresses by representatives of the organisations involved in helping Nikon Europe B.V. locate and develop the partnership with the Leiden Bio Science Park: Paul Dirkse, Vice Mayor of the City of Leiden; Hilde van der Meer, Commissioner, Netherlands Foreign Investment Agency; Chris van Voorden, Director Foreign Investments of InnovationQuarter; Ida Haisma, Director of Stichting Leiden Bio Science Park; Thijs de Kleer, Director of Biopartner Leiden, and Amito Haarhuis, Director of Rijksmuseum Boerhaave. Bo Kajiwara, Corporate Vice President, Nikon Corporation, Director & President, Nikon Europe B.V. led the opening program for Nikon Europe B.V.

The inauguration and ribbon cutting took place with a symbolic transfer of the famous 17th century van Leeuwenhoek’s microscope, by Amito Haarhuis. World famous for his pioneering work and discoveries in microscopy, Antonie van Leeuwenhoek developed this single-lens microscope, which proved capable of more powerful magnification than other lenses.

Takaharu Sasaoka, Director and Executive Vice President, Healthcare Business Head, Nikon Europe B.V., appreciates the symbolism of the microscope transfer, “It is very appropriate that Nikon, with over 100 years of expertise in optical technology, should open its first European Nikon BioImaging Lab (NBIL-Leiden) here in the Netherlands, the home of Antonie van Leeuwenhoek, the ‘father of microbiology’, whose systematic and extensive research laid the foundations of medical and scientific research. Our mission also is to advance healthcare and provide a better quality of life.

“We are very excited to be located here in the Leiden Bio Science Park, the largest life sciences cluster in the Netherlands, and I would like to thank all the organisations that helped Nikon Europe B.V. locate and develop this partnership. Following the success of our Nikon BioImaging Labs in the US and Japan, NBIL-Leiden will provide services for microscope-based imaging and analysis to the European biotech, pharma, and larger research communities. We are more than a core facility – our full-service capabilities include not only access to Nikon’s innovative microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.”

Daniel Ciepielewski, General Manager, Healthcare Division, Nikon Europe B.V., explains further, “NBIL-Leiden provides full-service imaging, data analysis, and cell cultures using cutting-edge Nikon microscope systems and software solutions, including the new laser scanning confocal AX R, the incubated high content imaging platform LIPSI, deep learning software NIS.ai, research inverted microscope Ti2-E, and compact live-cell imaging microscope BioStudio-T. Unlike other imaging facilities the lab offers full-service cell culture capabilities – our experienced staff is equipped to handle cell thawing, maintenance, expansion, differentiation, and other essential operations.

“The level of service and involvement of the lab is determined individually for each client based on need. Some need only access to equipment and are capable of data acquisition/analysis on their own, while others may require full-service imaging and analysis support. Additional applications include high content imaging and analysis, 3D imaging, fluorescence imaging, high-resolution imaging, color imaging, label-free imaging, cell screening and high throughput imaging, among others. NBIL-Leiden is now open, providing expert imaging support – on demand.”

Nikon Europe B.V. is grateful to InnovationQuarter, the regional economic development agency for the Province of Zuid-Holland, which assisted us in finding the right location and helped coordinate communication to develop the partnership with the Leiden Bio Science Park.

Nikon Europe B.V. is also grateful to the following contributing companies who have partnered with NBIL-Leiden: Clean Air Baker, PHC, Crest Optics, Photometrics, CoolLed, and Precipoint.

For further information, please contact: NBIL.EU@nikon.com
Or please visit www.microscope.healthcare.nikon.com/en_EU/products/cell-screening/nbil.

About Nikon Europe B.V.
Nikon Europe B.V. is the European microscopy arm of Nikon Healthcare Business Unit, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit www.microscope.healthcare.nikon.com/en_EU.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media information:
Ziryan Othman
Ziryan.Othman@nikon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 20:16:00 EEST | Press release

Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 19:16:00 EEST | Press release

Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure controlsoftware to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers. The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses. The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly fas

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 11:52:00 EEST | Press release

SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 08:10:00 EEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye